June 7 Synlogic:
* Synlogic says has completed first phase of its ongoing collaboration with AbbVie
* Synlogic - during first discovery phase Synlogic identified synthetic biotic leads for treatment of inflammatory bowel disease, including Crohn's Disease, colitis
* Synlogic says will receive an undisclosed milestone payment and companies will move into second phase of collaboration Source text for Eikon: Further company coverage:
WORLD NEWS SCHEDULE AT 1800 GMT/2 PM ET
Iraqi forces free hundreds of civilians in Mosul Old City battles as death toll mounts
CEO of Raytheon's Forcepoint eyes IPO -Boersen-Zeitung
FRANKFURT, June 24 U.S. missile maker Raytheon's cybersecurity unit could thrive were it to be listed separately, the head of the unit, Forcepoint, told German business daily Boersenzeitung in an interview published on Saturday.